Figure 3
From: New insights into quetiapine metabolism using molecular networking
Cytochrome inhibitors enable quetiapine metabolic pathway inhibition in differentiated HepaRG and primary Human hepatocytes (pHH). Cells were incubated with quetiapine (13 µM) with or without CYPs inhibitors (ketoconazole 10 µM as a CYP3A4/5 inhibitor in grey; quinidine 10 µM as a CYP2D6 inhibitor in red) in (a) differentiated HepaRG cells or (b) pHH. Quetiapine concentration was measured at H0, H3, H6, H8 and H24 using high-resolution liquid-chromatography and expressed relative to the value determined at H0 (set arbitrarily to 100%). The data are quoted as the mean ± SEM from one experiment performed in triplicate. Statistics (unpaired student’s t-test): ***p < 0.01 and *p < 0.05 for cultures exposed to quetiapine + CYP inhibitor (ketoconazole or quinidine) compared with quetiapine alone at different times.
